Shares in global pharmaceutical business Mayne Pharma Group Ltd (ASX: MYX) have bolted around 7 percent higher to $1.54 this morning after the company provided a business update at an investment conference this morning.

Mayne Pharma recently acquired a portfolio of 42 drug products from U.S. pharmaceutical giants Teva and Allergan for $652 million, although its share price has been volatile after news broke of a U.S. regulatory investigation into the marketing, sales, and pricing of drug products in the U.S. market.

Worryingly for investors the company has been subpoenaed by the U.S. Department of Justice (DOJ) to provide information over the sale of some of its drug products and it’s no surprise the shares were under selling pressure last week given the DOJ’s broad powers and fearsome reputation.

Mayne Pharma stated that it believes the investigations will not have a “material” impact on earnings, although it added the disclaimer that no assurance can be given as to the outcome of the investigation.

The stock is likely to trade sideways until the uncertainty around the DOJ’s investigation is lifted, even though Mayne Pharma boasts an attractive product portfolio in the world’s most lucrative healthcare market.

Investors looking for healthcare stocks sold down in the wake of U.S. election jitters may be better off looking at liver cancer specialist Sirtex Medical Limited (ASX: SRX) or hospital equipment provider Nanosonics Ltd (ASX: NAN).

How 1 Man Made 100x His Money After 50

Few know, that as Warren Buffett blew out the candles on his 50th birthday cake, he had just 1% of his current fortune. Think about it: At an age when most give up hope, Buffett was just getting started on the remaining 99% of his fortune. Goes to show you that it's never too late for you to potentially get rich. Which is why we've gathered the strategies we learned from Buffett, distilled them down to 11 simple lessons, and put it in an exclusive report for you to claim. Just click here to learn more about this handy investing guide.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Tom Richardson has no position in any stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.